TScan Therapeutics, Inc. (TCRX) Tops Q2 EPS by 3c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q2 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $1.88 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Microsoft plans data center push to triple its computing power - Bloomberg
• Openai Is Open To Slowing Cutting-edge Ai, Altman Tells Staff - Bloomberg
• Zumiez, Inc. (ZUMZ) Misses Q2 EPS by 6c, Misses on Revenue; Offers Q3 Guidance